# A Study of RAG-01 in Patients With Non-muscle-invasive Bladder Cancer (NMIBC) Who Have Failed Bacillus Calmette Guérin (BCG) Therapy

> **NCT06351904** · PHASE1 · RECRUITING · sponsor: **Ractigen Therapeutics.** · enrollment: 72 (estimated)

## Conditions studied

- Non-Muscle-Invasive Bladder Cancer (NMIBC)

## Interventions

- **DRUG:** RAG-01

## Key facts

- **NCT ID:** NCT06351904
- **Lead sponsor:** Ractigen Therapeutics.
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-04-03
- **Primary completion:** 2028-08-31
- **Final completion:** 2028-08-31
- **Target enrollment:** 72 (ESTIMATED)
- **Last updated:** 2025-09-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06351904

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06351904, "A Study of RAG-01 in Patients With Non-muscle-invasive Bladder Cancer (NMIBC) Who Have Failed Bacillus Calmette Guérin (BCG) Therapy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06351904. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*